Jonathan G. Seidman

Jonathan G. Seidman

Auto-generated profile, based on publicly available information

Jonathan G. Seidman

Department of Genetics, Harvard Medical School, Boston, MA 02115, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2020 in Nature
Verified
Journal Article
Open access
PDF file
MLMonika Litviňuková
Monika Litviňuková
CTCarlos Talavera-López
Carlos Talavera-López
HMHenrike Maatz
Henrike Maatz
DRDaniel Reichart
Daniel Reichart
CWCatherine L. Worth
Catherine L. Worth
STSarah A. Teichmann
Sarah A. Teichmann
Cardiovascular disease is the leading cause of death worldwide. Advanced insights into disease mechanisms and therapeutic strategies require a deeper understanding of the molecular processes involved in the healthy heart. Knowledge of the full repertoire of cardiac cells and their gene expression profiles is a fundamental first step in this endeavour. Here, using state-of-the-art analyses of large-scale single-cell and single-nucleus transcriptomes, we characterize six anatomical adult heart regions. Our results highlight the cellular heterogeneity of cardiomyocytes, pericytes and fibroblasts, and reveal distinct atrial and ventricular subsets of cells with diverse developmental origins and specialized properties. We define the complexity of the cardiac vasculature and its changes along the arterio-venous axis. In the immune compartment, we identify cardiac-resident macrophages with inflammatory and protective transcriptional signatures. Furthermore, analyses of cell-to-cell interactions highlight different networks of macrophages, fibroblasts and cardiomyocytes between atria and ventricles that are distinct from those of skeletal muscle. Our human cardiac cell atlas improves our understanding of the human heart and provides a valuable reference for future studies.

9 October 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
SJSheng Chih Jin
Sheng Chih Jin
JHJason Homsy
Jason Homsy
SZSamir Zaidi
Samir Zaidi
QLQiongshi Lu
Qiongshi Lu
SMSarah U. Morton
Sarah U. Morton
MBMartina Brueckner
Martina Brueckner
Exome sequencing of 2,871 probands with congenital heart disease (CHD) provides new insights into the genetic architecture of these disorders. The results implicate new genes in CHD pathogenesis and highlight striking overlap between genes with damaging de novo mutations in individuals with CHD and autism. Congenital heart disease (CHD) is the leading cause of mortality from birth defects. Here, exome sequencing of a single cohort of 2,871 CHD probands, including 2,645 parent–offspring trios, implicated rare inherited mutations in 1.8%, including a recessive founder mutation in GDF1 accounting for ∼5% of severe CHD in Ashkenazim, recessive genotypes in MYH6 accounting for ∼11% of Shone complex, and dominant FLT4 mutations accounting for 2.3% of Tetralogy of Fallot. De novo mutations (DNMs) accounted for 8% of cases, including ∼3% of isolated CHD patients and ∼28% with both neurodevelopmental and extra-cardiac congenital anomalies. Seven genes surpassed thresholds for genome-wide significance, and 12 genes not previously implicated in CHD had >70% probability of being disease related. DNMs in ∼440 genes were inferred to contribute to CHD. Striking overlap between genes with damaging DNMs in probands with CHD and autism was also found.

27 January 2005 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
MAMichael Arad
Michael Arad
BMBarry J. Maron
Barry J. Maron
JGJoshua M. Gorham
Joshua M. Gorham
WJWalter H. Jr. Johnson
Walter H. Jr. Johnson
JSJ. Philip Saul
J. Philip Saul
JSJ.G. Seidman
J.G. Seidman
Unexplained left ventricular hypertrophy often prompts the diagnosis of hypertrophic cardiomyopathy, a sarcomere-protein gene disorder. Because mutations in the gene for AMP-activated protein kinase γ2 (PRKAG2) cause an accumulation of cardiac glycogen and left ventricular hypertrophy that mimics hypertrophic cardiomyopathy, we hypothesized that hypertrophic cardiomyopathy might also be clinically misdiagnosed in patients with other mutations in genes regulating glycogen metabolism.

1 November 2016 in Developmental Cell
Verified
Journal Article
Closed access
DDDaniel M. DeLaughter
Daniel M. DeLaughter
ABAlexander G. Bick
Alexander G. Bick
HWHiroko Wakimoto
Hiroko Wakimoto
DMDavid McKean
David McKean
JGJoshua M. Gorham
Joshua M. Gorham
CSChristine Seidman
Christine Seidman

1 October 2010 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PTPolakit Teekakirikul
Polakit Teekakirikul
SESeda Eminaga
Seda Eminaga
OTOkan Toka
Okan Toka
RARonny Alcalai
Ronny Alcalai
LWLibin Wang
Libin Wang
JSJonathan G. Seidman
Jonathan G. Seidman
Mutations in sarcomere protein genes can cause hypertrophic cardiomyopathy (HCM), a disorder characterized by myocyte enlargement, fibrosis, and impaired ventricular relaxation. Here, we demonstrate that sarcomere protein gene mutations activate proliferative and profibrotic signals in non-myocyte cells to produce pathologic remodeling in HCM. Gene expression analyses of non-myocyte cells isolated from HCM mouse hearts showed increased levels of RNAs encoding cell-cycle proteins, Tgf-β, periostin, and other profibrotic proteins. Markedly increased BrdU labeling, Ki67 antigen expression, and periostin immunohistochemistry in the fibrotic regions of HCM hearts confirmed the transcriptional profiling data. Genetic ablation of periostin in HCM mice reduced but did not extinguish non-myocyte proliferation and fibrosis. In contrast, administration of Tgf-β–neutralizing antibodies abrogated non-myocyte proliferation and fibrosis. Chronic administration of the angiotensin II type 1 receptor antagonist losartan to mutation-positive, hypertrophy-negative (prehypertrophic) mice prevented the emergence of hypertrophy, non-myocyte proliferation, and fibrosis. Losartan treatment did not reverse pathologic remodeling of established HCM but did reduce non-myocyte proliferation. These data define non-myocyte activation of Tgf-β signaling as a pivotal mechanism for increased fibrosis in HCM and a potentially important factor contributing to diastolic dysfunction and heart failure. Preemptive pharmacologic inhibition of Tgf-β signals warrants study in human patients with sarcomere gene mutations.

13 October 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MPMichael Parfenov
Michael Parfenov
CPChandra Sekhar Pedamallu
Chandra Sekhar Pedamallu
NGNils Gehlenborg
Nils Gehlenborg
SFSamuel S. Freeman
Samuel S. Freeman
LDLudmila Danilova
Ludmila Danilova
ZZZhixiang Zuo
Zhixiang Zuo
Significance: A significant proportion of head and neck cancer is driven by human papillomavirus (HPV) infection, and the expression of viral oncogenes is involved in the development of these tumors. However, the role of HPV integration in primary tumors beyond increasing the expression of viral oncoproteins is not understood. Here, we describe how HPV integration impacts the host genome by amplification of oncogenes and disruption of tumor suppressors as well as driving inter- and intrachromosomal rearrangements. Tumors that do and do not have HPV integrants display distinct gene expression profiles and DNA methylation patterns, which further support the view that the mechanisms by which tumors with integrated and nonintegrated HPV arise are distinct.